OnabotulinumtoxinA Injection as an Adjunct in the Treatment of Posterior Shoulder Subluxation in Neonatal Brachial Plexus Palsy

Ezaki, Marybeth; Malungpaishrope, Kanchai; Harrison, Richard J.; Mills, Janith K.; Oishi, Scott N.; Delgado, Mauricio; Bush, Patricia A.; Browne, Richard H.
September 2010
Journal of Bone & Joint Surgery, American Volume;Sep2010, Vol. 92-A Issue 12, p2171
Academic Journal
Background: Botulinum toxin A is used to treat contractures in children with spasticity by temporarily interfering with neural transmission at the motor end plate. In infants with brachial plexus palsy, posterior shoulder subluxation and dislocation are the result of muscle imbalance, in which neurologic recovery is evolving, and spasticity is not a deforming force. We postulated that temporary weakening of the shoulder internal rotator muscles with botulinum toxin A would facilitate reduction of the glenohumeral joint in such infants with early posterior shoulder subluxation or dislocation. Methods: Thirty-five infants with posterior subluxation or dislocation of the shoulder due to brachial plexus palsy were treated with botulinum toxin A between January 1999 and December 2006, and were followed for a minimum period of one year. Records were reviewed for the severity of the palsy, age at time of treatment, recurrence of subluxation or dislocation, and the subsequent need for further treatment to reduce the glenohumeral joint. Results: The average age at the time of shoulder reduction and botulinum toxin-A injection was 5.7 months. Six patients had a second injection. Reduction of the shoulder was maintained in twenty-four (69%) of the thirty-five patients. There were no complications related to the use of botulinum toxin A. Conclusions: Although there may be specific risks associated with its use, botulinum toxin-A injection into the internal rotator muscles is a useful adjunct to the treatment of early posterior subluxation or dislocation of the shoulder in infants with neonatal brachial plexus palsy, and may help to avoid the need for open surgical procedures to restore or maintain shoulder reduction. Level of Evidence: Therapeutic Level IV. See Instructions to Authors for a complete description of levels of evidence.


Related Articles

  • Feasibility of Video Clip Analysis on Effect of Botulinum Toxin-A Injection for Post-Stroke Upper Limb Spasticity. Woo-Jin Kim; Kumthornthip, Witsanu; Byung Mo Oh; Eun Joo Yang; Nam-Jong Paik // Toxins;May2013, Vol. 5 Issue 5, p983 

    Existing functional evaluation tools do not accurately reveal the improved function following botulinum toxin A (BTX-A) injection for post-stroke upper limb spasticity. With the aim of developing an alternate method of measuring functional improvement following BTX-A injection, this study tested...

  • Botulinum toxin should be first-line treatment for poststroke spasticity. Sheean, Geoffrey // Journal of Neurology, Neurosurgery & Psychiatry;Apr2009, Vol. 80 Issue 4, p359 

    The article discusses the use of botulinum toxin in treating stroke spasticity in Great Britain. It helps prevent postural deformity, pain and impaired passive and active movement, and impaired function. The botulinum neurotoxin can also be used for treating in the abnormalities in shoulder...

  • Botulinum Toxin Physiology in Focal Hand and Cranial Dystonia. Karp, Barbara Illowsky // Toxins;Nov2012, Vol. 4 Issue 11, p1404 

    The safety and efficacy of botulinum toxin for the treatment of focal hand and cranial dystonias are well-established. Studies of these adult-onset focal dystonias reveal both shared features, such as the dystonic phenotype of muscle hyperactivity and overflow muscle contraction and divergent...

  • Botulinum toxin type B de novo therapy of cervical dystonia. Dressler, Dirk; Bigalke, Hans // Journal of Neurology;Aug2005, Vol. 252 Issue 8, p904 

    Botulinum toxin induced therapy failure type B antibody (BT–B, BT–B–AB) has so far only been reported after previous formation of antibodies against botulinum toxin type A (BT–A, BTA– AB).We wanted to explore the risk of BT-B-AB-induced therapy failure in...

  • Botulinum information.  // British Journal of Community Nursing;Dec2005, Vol. 10 Issue 12, p581 

    The article presents information about a leaflet entitled "Botulinum Toxin: Your Questions Answered," from Ipsen Ltd for people with dystonias. It was initially developed to help the Dystonia Society, the organization dedicated to support of people affected by dystonia, answer questions from...

  • Efficacy of botulinum toxin for spasticity management in neurorehabilitation. Kulkarni, Jai // International Journal of Therapy & Rehabilitation;May2004, Vol. 11 Issue 5, p211 

    Presents the study assessing the effect of botulinum toxin type A when used in conjunction with physiotherapy on spasticity management. Identification of the most potent toxins available proved to be a remarkable therapeutic agent when used appropriately; Effect of spasticity on joint movement...

  • The value of local botulinum toxin A injection in the treatment of the pain of aphthous ulcer. Tae Yong Yang; Tae Yong Jang // European Archives of Oto-Rhino-Laryngology;Mar2009, Vol. 266 Issue 3, p445 

    To determine the effectiveness of botulinum toxin type A to reduce pain of recurrent aphthous ulcer, a single blinded placebo controlled trial of botulinum toxin A injection was performed. A total of 70 patients were enrolled and randomly received a botulinum toxin type A 1 unit or placebo. The...

  • Associative Stimulation of the Supraorbital Nerve Fails to Induce Timing-Specific Plasticity in the Human Blink Reflex. Zeuner, Kirsten E.; Knutzen, Arne; Al-Ali, Asmaa; Hallett, Mark; Deuschl, Günther; Bergmann, Til O.; Siebner, Hartwig R. // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: Associative high-frequency electrical stimulation (HFS) of the supraorbital nerve in five healthy individuals induced long-term potentiation (LTP)-like or depression (LTD)-like changes in the human blink reflex circuit according to the rules of spike timing-dependent plasticity (Mao...

  • How to obtain optimum results with botulinum toxin. Charles, Lynda // Ophthalmology Times;5/1/2004, Vol. 29 Issue 9, p64 

    Shows how ophthalmologists can obtain the best results with botulinum toxin injections. Goals of cosmetic botulinum toxin ; Pre-procedure assessment; Correct dosage; Depth of injections; Other requirements for doing the procedure correctly.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics